The drug/biotech sector’s reporting cycle is approaching its end. All big drugmakers have already reported their results. The large drugmakers mostly reported disappointing first-quarter 2021 results with many companies missing estimates for both earnings and sales. A few like Pfizer, AstraZeneca, AbbVie and J&J reported better-than-expected results.
Per the Zacks classification, the pharma/biotech industry comes under the broader
Medical sector, which comprises pharma/biotech as well as medical device companies.
Earnings Trends report as of May 4, 75.9% of the companies in the Medical sector, constituting nearly 86.6% of the sector’s market capitalization, reported earnings. While 78.0% beat earnings estimates, 68.3% beat the same for sales. Earnings increased 22% year over year on 13.2% higher revenues. Overall, first-quarter earnings for the Medical sector are expected to rise 23.6% on 10.6% sales increase.
Let’s analyze the three drug/biotech companies that are set to report first-quarter 2021 results on May 7.
Radius Health RDUS
Radius Health has a poor earnings track record. It missed earnings estimates thrice in the past four quarters while delivering in-line results in one, recording an average negative earnings surprise of 18.03%.
This small biotech focused on the development of endocrine therapeutics in the areas of osteoporosis and oncology has an
Earnings ESP of -17.37% and a Zacks Rank #3 (Hold).
The Zacks Consensus Estimate for loss stands at 42 cents per share.
Per our proven model, stocks with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 have a good chance of delivering earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our
Earnings ESP Filter. Cronos Group Inc. ( CRON Quick Quote CRON - Free Report)
This medical marijuana company’s earnings beat the Zacks Consensus Estimate in two of the last four quarters while missing in the other two, the average negative surprise being 3.58%.
This Zacks Rank #5 (Strong Sell) company has an Earnings ESP of 0.00%. The Zacks Consensus Estimate for loss stands 9 cents per share.
Ocugen ( OCGN Quick Quote OCGN - Free Report)
The company has a disappointing earnings surprise history, having missed expectations in the past three quarters. The average three-quarter negative earnings surprise was 274.44%.
Ocugen has an Earnings ESP of 0.00% and a Zacks Rank #5.
You can see
the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for earnings stands at 50 cents per share.
Investors are likely to focus on updates on
Ocugen’s gene therapy candidate, OCU400, on the first-quarter call. Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020 Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2021 today >>